A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract ...

Clinical outcomes in metastatic bladder cancer associated with mutations in Trithorax-group protein genes. Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract ...

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

There are different stages of bladder cancer depending on how the tumor has spread. The staging of bladder cancer can help a medical professional map out the best treatment plan and improve a person’s ...